KR20240044409A - Wee1 키나아제 저해제로서 유용한 피리도피리미딘 유도체 - Google Patents

Wee1 키나아제 저해제로서 유용한 피리도피리미딘 유도체 Download PDF

Info

Publication number
KR20240044409A
KR20240044409A KR1020247000364A KR20247000364A KR20240044409A KR 20240044409 A KR20240044409 A KR 20240044409A KR 1020247000364 A KR1020247000364 A KR 1020247000364A KR 20247000364 A KR20247000364 A KR 20247000364A KR 20240044409 A KR20240044409 A KR 20240044409A
Authority
KR
South Korea
Prior art keywords
cancer
tumor
compound
lymphoma
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247000364A
Other languages
English (en)
Korean (ko)
Inventor
오렌 길라드
조셉 바카
Original Assignee
아프레아 테라퓨틱스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아프레아 테라퓨틱스, 인크. filed Critical 아프레아 테라퓨틱스, 인크.
Publication of KR20240044409A publication Critical patent/KR20240044409A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020247000364A 2021-06-04 2022-06-03 Wee1 키나아제 저해제로서 유용한 피리도피리미딘 유도체 Pending KR20240044409A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163196744P 2021-06-04 2021-06-04
US63/196,744 2021-06-04
PCT/US2022/032203 WO2022256680A1 (en) 2021-06-04 2022-06-03 Pyridopyrimidine derivatives useful as wee1 kinase inhibitors

Publications (1)

Publication Number Publication Date
KR20240044409A true KR20240044409A (ko) 2024-04-04

Family

ID=82321319

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247000364A Pending KR20240044409A (ko) 2021-06-04 2022-06-03 Wee1 키나아제 저해제로서 유용한 피리도피리미딘 유도체

Country Status (10)

Country Link
US (1) US20240254123A1 (https=)
EP (1) EP4347592A1 (https=)
JP (1) JP2024522304A (https=)
KR (1) KR20240044409A (https=)
CN (1) CN117794932A (https=)
AU (2) AU2022287033B2 (https=)
CA (1) CA3225152A1 (https=)
IL (1) IL309037A (https=)
MX (1) MX2023014466A (https=)
WO (1) WO2022256680A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL315441A (en) 2022-03-07 2024-11-01 Debiopharm Int Sa Treatment methods for small cell lung cancer
IL326854A (en) 2023-09-14 2026-04-01 Debiopharm Int Sa Combination of WEE1 inhibitor and PKMYT1 inhibitor
CN120189510A (zh) * 2023-12-21 2025-06-24 北京哲源科技有限责任公司 一种并环化合物的应用
TW202541810A (zh) 2023-12-22 2025-11-01 瑞士商德彪製藥國際公司 治療實體腫瘤之方法
WO2025186213A1 (en) 2024-03-04 2025-09-12 Debiopharm International S.A. Combination of a wee1 inhibitor and a topoisomerase 1 inhibitor

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002098370A2 (en) 2001-03-02 2002-12-12 Medimmune, Inc. Methods of administering/dosing cd2 antagonists for the prevention and treatment of autoimmune disorders or inflammatory disorders
AR060635A1 (es) * 2006-04-27 2008-07-02 Banyu Pharma Co Ltd Derivados de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona, composiciones farmaceuticas que los comprenden y su uso en el tratamiento del cancer
CN104271576A (zh) * 2012-02-23 2015-01-07 艾伯维公司 激酶的吡啶并嘧啶酮抑制剂
GB201306610D0 (en) * 2013-04-11 2013-05-29 Almac Discovery Ltd Pharmaceutical compounds
GB201612095D0 (en) * 2016-07-12 2016-08-24 Almac Discovery Ltd Pharmaceutical compounds
CA3071405A1 (en) * 2017-08-01 2019-02-07 Recurium Ip Holdings, Llc 1, 2 - dihydro- 3h- pyrazolo [3, 4 - d] pyrimidin -3 - one analogs
GB201800378D0 (en) * 2018-01-10 2018-02-21 Almac Discovery Ltd Pharmaceutical compounds

Also Published As

Publication number Publication date
AU2025204724A1 (en) 2025-07-10
CA3225152A1 (en) 2022-12-08
AU2022287033A1 (en) 2024-01-18
AU2022287033B2 (en) 2025-04-17
CN117794932A (zh) 2024-03-29
WO2022256680A1 (en) 2022-12-08
US20240254123A1 (en) 2024-08-01
IL309037A (en) 2024-02-01
MX2023014466A (es) 2024-05-02
EP4347592A1 (en) 2024-04-10
JP2024522304A (ja) 2024-06-13

Similar Documents

Publication Publication Date Title
KR20240044409A (ko) Wee1 키나아제 저해제로서 유용한 피리도피리미딘 유도체
AU2022202686B2 (en) Methods of treating and preventing graft versus host disease
CN113453684B (zh) 用于治疗癌症的csf1r抑制剂
US20240316004A1 (en) Methods of treating mutant lymphomas
TWI586354B (zh) 布魯頓氏酪胺酸激酶（ｂｒｕｔｏｎ'ｓ ｔｙｒｏｓｉｎｅ ｋｉｎａｓｅ ）抑制劑之組合及其用途
CN104039325A (zh) 布鲁顿酪氨酸激酶(btk)抑制剂的用途
CA2932255A1 (en) Methods of treating and preventing alloantibody driven chronic graft versus host disease
KR20250067120A (ko) 의학적 치료를 위한 시클린-의존성 키나제 2 억제제
HK40107981A (zh) 可用作wee1激酶抑制剂的吡啶并嘧啶衍生物
HK40086449A (en) Methods of treating and preventing graft versus host disease
HK40024250A (en) Use of inhibitors of bruton's tyrosine kinase (btk)

Legal Events

Date Code Title Description
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

D21 Rejection of application intended

Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE)

PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13 Application amended

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000